24
Participants
Start Date
May 31, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
The TGFβi NK cell product will be manufactured in the Cell Therapy Laboratory at Nationwide Children's Hospital and given via infusion.
Implantation
Undergo placement of Ommaya reservoir
Magnetic Resonance Imaging (MRI)
Imaging procedure
Quality-of-Life Assessment
Ancillary studies
RECRUITING
Johns Hopkins, Baltimore
RECRUITING
University of Alabama Birmingham, Birmingham
RECRUITING
Indiana University, Indianapolis
RECRUITING
Washington University in Saint Louis, St Louis
RECRUITING
University of California, San Francisco, San Francisco
RECRUITING
Hackensack University Medical Center, Hackensack
Collaborators (1)
Rally Foundation
UNKNOWN
Washington University School of Medicine
OTHER
Nationwide Children's Hospital
OTHER
CureSearch
UNKNOWN
Tommy Strong Foundation
UNKNOWN
Sabine Mueller, MD, PhD
OTHER